Title: A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma
- Principal Investigator: Dr. Jesse Keller
- Study Coordinator: Maureen Dempsey
This phase 3 study will evaluate the superiority of the fixed dose combination (FDC) of fianlimab + cemiplimab versus the FDC of relatlimab + nivolumab (referred to as Opdualag) in participants with unresectable locally advanced or metastatic melanoma. Opdulag is approved in the US for treatment of patients with unresectable or metastatic melanoma.
This study is administered by VREF and funded by Regeneron.
Find Out More
This study is currently enrolling patients. To learn more about this study and how you can join contact our research office at (314) 289-7690.
If you are a veteran receiving care through the VA St. Louis Health Care System and believe you may be eligible for this study, please speak with your Physician. For general information about our research, please visit our main Clinical Trials page or contact us directly.